Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province

References 

• Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378(9799):1297–1305.
   PubMed Web of Science ®Google Scholar
• Sabatini MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328–332.
   PubMed Web of Science ®Google Scholar
• Zheng X, Fang P, Bao SS, et al. Function of 38 variants CYP2C9 polymorphism on ketamine metabolism in vitro. J Pharmacol Sci. 2017;135:8–13.
   PubMed Web of Science ®Google Scholar
• Chhonker YS, Chandasana H, Bala V, et al. In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent. J Pharm Biomed Anal. 2018;160:202–211.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–165.
   PubMed Web of Science ®Google Scholar
• Eltalal S, Ayouty ME, El-Said A, et al. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children. Acta Neurol Belg. 2021;121(6):1623–1631.
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–2247.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304(16):1821–1830.
   PubMed Web of Science ®Google Scholar
• PharmaVar. Pharmacogene Variation Consortium; 2021. Available from: https://www.pharmvar.org/gene/CYP2C19.
   Google Scholar
• Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. J Am Coll Cardiol. 2010;56(2):134–143.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cyto-chrome P450 2C19-genotyped subgroups: Integration of the TRITON-TIMI38 trial data. J Thromb Haemost. 2010;8(8):1678–1684.
   PubMed Web of Science ®Google Scholar
• Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members, et al. ACCF/AHA Clopidogrel clinical alert: Approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122(5):537–557.
   PubMed Web of Science ®Google Scholar
• Shuldiner DAR, O’Connell DJR, Bliden MKP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857.
   PubMed Web of Science ®Google Scholar
• Kobori L, Kohalmy K, Porrogi P, et al. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br J Clin Pharmacol. 2008;65(3):428–436.
   PubMed Web of Science ®Google Scholar
• Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15(12):1929–1937.
   PubMed Web of Science ®Google Scholar
• Shimatani T, Inoue M, Kuroiwa T, et al. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther. 2003;18(11–12):1149–1157.
   PubMed Web of Science ®Google Scholar
• Yamada H, Dahl ML, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol. 1998;54(6):479–481.
   PubMed Web of Science ®Google Scholar
• Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59(4):303–312.
   PubMed Web of Science ®Google Scholar
• Scordo MG, Caputi AP, D’Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004;50(2):195–200.
   PubMed Web of Science ®Google Scholar
• Bravo-Villalta HV, Yamamoto K, Nakamura K, et al. Genetic polymorphism of CYP2C9 and CYP2C19 in a bolivian population: an investigative and comparative study. Eur J Clin Pharmacol. 2005;61(3):179–184.
   PubMed Web of Science ®Google Scholar
• Halling J, Petersen MS, Damkier P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005;61(7):491–497.
   PubMed Web of Science ®Google Scholar
• Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*. Clin Pharmacol Ther. 1998;64(4):391–401.
   PubMed Web of Science ®Google Scholar
• Persson I, Aklillu E, Rodrigues F, et al. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among ethiopians. Pharmacogenetics. 1996;6(6):521–526.
   PubMedGoogle Scholar
• Masimirembwa C, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a shona population of Zimbabwe*. Clin Pharmacol Ther. 1995;57(6):656–661.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Hou J, Li B, et al. Analysis of CYP2C19 genetic polymorphism in a large Ethnic Hakka population in Southern China. Med Sci Monit. 2017;23:6186–6192.
   PubMed Web of Science ®Google Scholar
• He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol. 2002;58(1):15–18.
   PubMed Web of Science ®Google Scholar
• Ding Y, Xu D, Zhang X, et al. Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population. Int J Clin Exp Pathol. 2015;8(10):13201–13208.
   PubMed Web of Science ®Google Scholar
• Zuo LJ, Guo T, Xia DY, et al. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers. 2012;16(2):102–108.
   PubMed Web of Science ®Google Scholar
• Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20(3):243–247.
   PubMed Web of Science ®Google Scholar
• Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001;36(10):669–672.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Tunthong R, Chamnanphon M, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med. 2013;6:85–91.
   PubMedGoogle Scholar